A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CMZ / cefmetazole

[Related PubMed/MEDLINE]
Total Number of Papers: 158
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CMZ  (>> Co-occurring Abbreviation)
Long Form:   cefmetazole
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 In Vitro Efficacy of Meropenem-Cefmetazole Combination Therapy against New Delhi Metallo-beta-lactamase-producing Enterobacteriaceae. ERT, MEM, MICs, NDM
2019 Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae. CRE, IMP, MEM, MICs
2019 Change in the Antimicrobial Resistance Profile of Extended-Spectrum beta-Lactamase-Producing Escherichia coli. AMK, CPFX, ESBL-EC, FMOX, GM, IPM, LVFX, MEPM, MINO, non-ESBL-EC
2019 In Vitro Effectiveness of Meropenem and Cefmetazole Combination Treatment Against KPC-2-Producing Enterobacteriaceae. CFU, CPE, ERT, MEM
2019 Induction of plasmid-mediated AmpC beta-lactamase DHA-1 by piperacillin/tazobactam and other beta-lactams in Enterobacteriaceae. PIP/TZB
2018 [Drug-induced immune hemolytic anemia caused by cefmetazole]. DIIHA, Hb
2017 Bacteraemic urinary tract infections in a tertiary hospital in Japan: the epidemiology of community-acquired infections and the role of non-carbapenem therapy. CBP, ESBL-PE, non-CBPBL, PT, UTIs
2017 Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital. CRP, E. coli, ESBL, SOFA, TAZ/PIPC
2017 Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli. E. coli, ESBL, FMOX, FOM, IPM/CS, UTI
10  2017 Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer. PK/PD
11  2013 [Antimicrobial activity of several drugs against extended-spectrum beta-lactamase positive Enterobacteriaceae isolates in Gifu and Aichi prefecture]. DRPM, ESBL, IPM, MEPM, TAZ/PIPC
12  2012 Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion. CEZ, CTM, FMOX, PAA, TAZ/PIPC
13  2007 Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. AST
14  2007 Effects of air tourniquet on the antibiotics concentration, in bone marrow, injected just before the start of operation. MIC, THA, TKA
15  2007 Humanization of excretory pathway in chimeric mice with humanized liver. SCID, uPA
16  2007 [Fundamental study on the selection of antimicrobial prophylactic agents in abdominal surgery]. CEZ, CTM
17  2006 Determination of cefmetazole residue at pharmaceutical manufacturing facilities by chemiluminescence flow injection analysis. FIA
18  2006 LC/MS/MS method for the determination of trace amounts of cefmetazole and cefpodoxime proxetil contaminants in pharmaceutical manufacturing environments. CPDX-PR
19  2006 Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry. CPDX-PR, OLM
20  2006 [Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery]. FMOX, FOM
21  2004 Influence of various antimicrobial agents on the intestinal flora in an intestinal MRSA-carrying rat model. CEZ, FMOX, MRSA, PIPC
22  2003 Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. ABK, CTM, FMOX, FOM, IPM, MINO, MRSA, OFLX, PAPM, SBT/CPZ, VCM
23  2003 [Antimicrobial activity of fosfomycin against beta-lactamase-producing methicillin-sensitive Staphylococcus aureus and methicillin-sensitive coagulase-negative staphylococci]. CEZ, CTM, FOM, MSCNS, MSSA, PIPC
24  2003 [Successful combination therapy of teicoplanin with cefmetazole on postoperative cardiovascular MRSA infections: clinical report on two cases]. MRSA, TEIC
25  2003 [Surveillance of susceptibility of clinical isolates to cefmetazole between 2000 and 2002]. CEZ, CTM, FMOX, SBT/CPZ
26  2001 [A questionnaire survey on the theory of postoperative infection prophylaxis in gynecology]. AMP, CEZ, CTM, FMOX
27  2001 [Immunological properties of S-1090, cefmatilen hydrochloride hydrate]. ASA, CET, CTM, ELISA, PCA, PCG
28  2000 [Combination effect of teicoplanin and beta-lactams on MRSA]. CFPM, FMOX, PAPM
29  1999 Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. CEZ, CPZ, CTM, FMOX, G-CSF, HGF, LMOX, PBP3, TNF-alpha
30  1999 [A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-negative bacilli]. AMK, FOM, GM, LMOX, MINO, ST
31  1998 Treatment of osteomyelitis with antibiotic-soaked porous glass ceramic. AW-GC, HA, ISP
32  1998 [A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-positive cocci and gram-negative cocci]. CCL, LMOX, MINO, OFLX, ST, VCM
33  1998 [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution]. ABK, AMK, CAM, CCL, CEZ, CFIX, CPFX, CPR, CPZ, CRMN, CTM, CZOP, FMOX, GM, IPM, LMOX, MINO, OFLX, TFLX, UTIs, VCM
34  1997 Inhibitory effects of antibiotics on platelet aggregation in vitro. ADP, AZT, CMD, CTM, FMOX, LMOX
35  1997 [Combination use of second generation cephem and isepamicin for the treatment of post-surgical infection of the lower digestive tract]. CTM, CXM, ISP
36  1996 [The evaluation of cefmetazole in clinical use. The study group of cefmetazole in clinical use]. ---
37  1996 [The taxonomic distribution, characteristic and susceptibility against antimicrobial agents of methicillin-resistant staphylococci isolated from blood]. CCL, CET, FMOX, FOM, MRCNS, MRSA
38  1995 [Lytic action of cefminox against slowly growing bacteria]. CMNX, E. coli
39  1994 [Antigenicity tests of tazobactam/piperacillin, tazobactam and piperacillin]. ASA, CET, PCA, PCG, PHA, PIPC, TAZ, TAZ/PIPC
40  1994 [Efficacy of combination therapy against MRSA in Ibaraki Prefecture]. ABK, CAZ, FMOX, FOM, MRSA, PIPC
41  1994 [Pharmacokinetic and clinical studies on cefozopran in the field of pediatrics]. CAZ, CZON, CZOP, FMOX, MRSA
42  1993 [Antimicrobial activities of arbekacin against methicillin-resistant Staphylococcus aureus isolated from patients of a pediatrics ward]. ABK, FOM, IPM, MIC, MRSA, VCM
43  1993 [Enhancement of in vitro antimicrobial activity of cefmetazole and cefazolin in combination against methicillin-resistant Staphylococcus aureus studies by checkerboard MIC method and disc diffusion method using discs containing both drugs]. CEZ, MRSA, MSSA
44  1993 [Enhancement of in vitro antimicrobial activity of cefmetazole and cefotiam in combination against methicillin-susceptible and -resistant Staphylococcus aureus studied using checkerboard MIC method and disc diffusion method with discs containing both drugs]. CTM, MRSA, MSSA
45  1992 Comparisons of the bacterial flora in genital regions at non-pregnancy. ---
46  1992 Improved survival in mice with diet-induced pancreatitis treated with new potent protease inhibitor, E-3123 and a broad spectrum antibiotic, cefmetazole. ---
47  1992 Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition. subMICs
48  1992 [A case of staphylococcal enterocolitis caused by methicillin resistant Staphylococcus aureus]. MRSA, TSST-I
49  1992 [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. IV. Combined effects of arbekacin with cefmetazole or flomoxef]. ABK, FMOX, MRSA
50  1992 [Evaluation of in vitro antimicrobial activity of cefazolin alone and in combination with cefmetazole or flomoxef using agar dilution method and disk diffusion method]. CEZ, FMOX
51  1992 [In vitro study on efficacy of combination use of aspoxicillin and beta-lactam preparations (ceftazidime, cefmetazole and aztreonam) against bacteria isolated from abdominal infections]. ASPC, AZT, CAZ
52  1990 [A study of tissue transfer of cefmetazole in the blood and uterus in pregnant rabbits]. ---
53  1990 [Clinical evaluation of aztreonam for infections accompanying febrile neutropenic children with hematologic disorders and solid tumors. A cooperative study]. AMK, AZT, PIPC
54  1990 [Comparative study of the bacterial flora in both uterocervical and uterine regions]. ---
55  1990 [Hospital and district differences in susceptibilities to antibiotics of main clinical isolates]. CEZ, GM
56  1990 [In vitro susceptibility of Escherichia coli and Klebsiella sp. to antibiotics]. CTM, CTT, CZX, GM, LMOX, NTL
57  1990 [Long-term surviving child with acute lymphoblastic leukemia complicated with legionellosis]. ALL, EM, LCM, MINO
58  1990 [Susceptibilities of uropathogenic bacteria to ampicillin, cefazolin, cefmetazole and gentamicin. Nine-year survey of changing patterns of susceptibilities]. CEZ, GM
59  1990 [Therapeutic effects of a combination treatment with cefmetazole and netilmicin against infections complicated with hematological disorders]. NTL
60  1989 Differential effects of cefmetazole sodium on the reproductive system of infant and pubertal male rats. NMTT
61  1989 [A successful treatment of an infective endocarditis caused by methicillin-resistant Staphylococcus aureus with a combination of cefmetazole with fosfomycin]. FOM, MRSA
62  1989 [Antibiotics-induced agranulocytosis. Patient's IgG inhibits a GM colony formation]. ---
63  1989 [Clinical experience of chemotherapy with cefmetazole for severe infections accompanying malignant hematological disorders]. ---
64  1989 [Detection of inducible beta-lactamase in sputum--clinical studies on Pseudomonas respiratory infection]. PIPC
65  1989 [Determination of the MIC of cefotetan against freshly isolated gram-negative bacilli]. CEZ, CFX, CTT, LMOX
66  1989 [Pharmacokinetic, bacteriological and clinical evaluation of sulbactam/ampicillin in pediatrics]. CEZ, PIPC
67  1989 [Urinary tract infection associated with urinary calculi. 2. Effects of antibiotics on bacteria within infected stones]. ---
68  1988 [A nationwide study of the antimicrobial susceptibility of clinical isolates of Staphylococcus aureus in Japan]. CEZ, GM
69  1988 [Antibacterial activity of human cervical mucus]. ---
70  1988 [Clinical study of postoperative infection of gastrointestinal cancer. Randomized study of preventive efficacy of cefmetazole versus cephalothin in postoperative infection of gastric and colorectal cancer]. ---
71  1988 [In vitro susceptibilities of clinical isolates of Staphylococcus aureus]. CEZ, CMX, FOM, LMOX, MINO, NFLX
72  1988 [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration]. CER, CEZ
73  1988 [Penetration of cefmetazole and netilmicin into the cerebrospinal fluid]. CSF, NTL
74  1987 [Antibacterial activities of various aminoglycosides against clinically isolated methicillin-resistant Staphylococcus aureus]. AGs, AMK, CEZ, DKB, GM, MRSA, NTL, SISO, TOB
75  1987 [Clinical evaluation of cefuzonam in pediatrics and a study on the penetration into cerebrospinal fluid]. CEZ, CMX, CPZ, CTM
76  1987 [Clinical study on effects of cefmetazole on severe infections accompanied by hematologic diseases]. ---
77  1987 [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1985). I. Susceptibility distribution]. AZT, CCL, CEZ, CFX, CMX, CPZ, CRMN, CTM, CTX, CZX, LMOX, NA, OFLX, PPA, ST
78  1987 [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1985). III. Secular changes in susceptibility]. AZT, CCL, CEX, CEZ, CFX, CMX, CPZ, CRMN, CTM, CTX, CZX, LMOX, OFLX
79  1987 [Free methyltetrazolethiol concentrations in men subjected to intravenous administration of cephems with methyltetrazolethiol]. CPZ, LMOX
80  1987 [Fundamental and clinical studies on cefuzonam in the field of pediatrics]. CEZ, CMX, CPZ, CTM, LMOX
81  1987 [Fundamental and clinical studies on cefuzoname in the pediatric field]. CEZ, CMD, CMX, CSF, CZON, LMOX
82  1987 [Laboratory and clinical studies of flomoxef]. CEZ, LMOX
83  1987 [Nationwide study of the antimicrobial susceptibility of clinical isolates of Proteus group in Japan]. CEZ, GM
84  1987 [Pharmacokinetics of cefmetazole during and after surgical operations]. AUCs, HPLC
85  1987 [Susceptibility of clinical isolates to aztreonam]. AZT, CFS, CPZ, CTX, LMOX
86  1986 [A nationwide study of the antimicrobial susceptibility of clinical isolates of Escherichia coli in Japan]. CEZ, GM
87  1986 [A nationwide study of the antimicrobial susceptibility of clinical isolates of Klebsiella sp. in Japan]. CEZ, GM
88  1986 [A study on the disulfiram-like reaction of T-2588. Influence of the consecutive administration of T-2588 on hepatic alcohol dehydrogenase and aldehyde dehydrogenase activities and blood levels of ethanol and acetaldehyde]. CEX
89  1986 [Antibiotic susceptibility of bacteria isolated from surgical infections (first report)]. AMK, CET, CEZ, CMX, CPZ, CTM, CTX, CZX, GM, LCM, LMOX, PIPC
90  1986 [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). I. Susceptibility distribution]. CCL, CMX, CPZ, CTM, CTX, CZX, LMOX, PPA
91  1986 [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility]. CCL, CEX, CEZ, CMX, CTM, CZX, LMOX, UTI
92  1986 [Comparison of in vitro activities of first, second and third generation cephem antibiotics against various pathogens isolated from clinical material in 1985]. CET, CEX, CEZ, CFS, CFX, CMX, CPZ, CTM, CTX, CZX, LMOX
93  1986 [Effect of cefminox on bacterial flora in human adult feces]. CMNX, CTX
94  1986 [Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. CAZ, CEZ, CFS, CMD, CPZ, CZX, LMOX, PIPC
95  1986 [In vitro susceptibility of bacterial isolates from patients with respiratory tract infections to beta-lactam antibiotics]. CEZ, CMX, CTM
96  1986 [In vivo antibacterial activity of cefbuperazone. Synergy of cefbuperazone for bactericidal effect with human polymorphonuclear leukocytes]. CPBZ, CPZ, CTT, LMOX
97  1986 [Transference of antibiotics into prostatic tissues: sampling method by transurethral resection for the measurement of the concentration of antibiotics in prostatic tissue]. FOM, TURP
98  1985 Cefmetazole: a broad spectrum cephem antibiotic effective on methicillin- and cephem-resistant Staphylococcus aureus. PBP
99  1985 Cefmetazole: clinical evaluation of efficacy and safety in Japan. CPZ, LMOX, Me-TZ
100  1985 Improvement of bioavailability of poorly absorbed drugs. V. Effect of surfactants on the promoting effect of medium chain glyceride for the rectal absorption of beta-lactam antibiotics in rats and dogs. MCG